Although RSV is a frequent cause of acute respiratory infections (ARIs), an estimation of its incidence has proven challenging due to a lack of routine testing, overlapping clinical presentations with ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates effectiveness against infections and associated hospitalizations in veterans aged 60 years or older during the ...

The respiratory syncytial virus prefusion F protein (RSVpreF) vaccine was highly effective against RSV-related acute respiratory illness (ARI) requiring emergency care or hospitalization, including in ...

Flu and Covid, including a new variant called BA.3.2, nicknamed “cicada,” are still circulating across the U.S. in 2026. How ...

A quadruple whammy of viruses – flu, COVID, norovirus, and respiratory syncytial virus, or RSV – is hitting the U.S. as the year comes to a close. The Centers for Disease Control and Prevention has ...

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing medically attended infections and hospitalizations. Maternal vaccination and ...

Young infants hospitalized with respiratory syncytial virus (RSV) often become much sicker than those infected with SARS-CoV-2, the virus that causes COVID-19. In a study published in Science ...

Cases of a specific respiratory virus are spiking in several states across the U.S. right now. In California, concentrations ...

While monoclonal antibodies have been approved to treat respiratory syncytial virus (RSV) in infants and young children in Germany, the German regulatory body for vaccinations—the German National ...